UDJ Stock Overview
A biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 3 more risks
Applied DNA Sciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.66 |
| 52 Week High | US$33.22 |
| 52 Week Low | US$4.66 |
| Beta | 0.082 |
| 11 Month Change | 0% |
| 3 Month Change | -21.02% |
| 1 Year Change | -81.24% |
| 33 Year Change | -94.91% |
| 5 Year Change | -97.64% |
| Change since IPO | -99.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| UDJ | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 0% | -6.0% | -0.4% |
| 1Y | -81.2% | 1.4% | 7.1% |
Return vs Industry: UDJ underperformed the German Life Sciences industry which returned -17.7% over the past year.
Return vs Market: UDJ underperformed the German Market which returned 0.9% over the past year.
Price Volatility
| UDJ volatility | |
|---|---|
| UDJ Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 6.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: UDJ's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine UDJ's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 54 | James Hayward | www.adnas.com |
Applied DNA Sciences, Inc., a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment develops and commercializes the LinearDNA platform, which enables a cell-free manufacture of high-fidelity synthetic DNA sequences for use in nucleic acid-based therapeutics.
Applied DNA Sciences, Inc. Fundamentals Summary
| UDJ fundamental statistics | |
|---|---|
| Market cap | €3.78m |
| Earnings (TTM) | -€11.48m |
| Revenue (TTM) | €5.07m |
0.7x
P/S Ratio-0.3x
P/E RatioIs UDJ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| UDJ income statement (TTM) | |
|---|---|
| Revenue | US$5.52m |
| Cost of Revenue | US$3.64m |
| Gross Profit | US$1.88m |
| Other Expenses | US$14.38m |
| Earnings | -US$12.50m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.22 |
| Gross Margin | 33.98% |
| Net Profit Margin | -226.55% |
| Debt/Equity Ratio | 0% |
How did UDJ perform over the long term?
See historical performance and comparison